Ardelyx's tenapanor for IBS-C presents positive global endpoint data
Ardelyx presentated positive global endpoint data from its Phase 2b trial, completed in September 2014, which evaluated tenapanor for the treatment of patients with irritable bowel syndrome with constipation. The company is also evaluating tenapanor in a Phase 3 study for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, with data expected to be reported in 1Q17. The IBS symptom global endpoints in the Phase 2b study included: adequate IBS symptom relief; improvements in IBS severity, constipation severity and treatment satisfaction. Compared to placebo, treatment with 50 mg of tenapanor twice a day resulted in statistically significant improvements in all global endpoints measured. 63.1% of patients treated with 50 mg of tenapanor twice a day reported adequate relief of IBS symptoms compared to 39.3% for patients on placebo.